The company's low-fat and non-fat varieties of ice cream appeal to health and calorie conscious consumers and are made using organic and natural ingredients, enabling users to experience healthy variants of ice cream. This is usually characteristic of DISTRIBUTION; however, price did not close below support. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Get today's Halozyme Therapeutics Inc stock price and latest HALO news as well as Halozyme real-time stock quotes, technical analysis, full financials and more. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Shares of HALO can be purchased through any online brokerage account. Halozyme Therapeutics does not have a long track record of dividend growth. Earnings for Halozyme Therapeutics are expected to grow by 81.05% in the coming year, from $0.95 to $1.72 per share. Get daily stock ideas top-performing Wall Street analysts. Specifically, they have bought $0.00 in company stock and sold $5,450,000.00 in company stock. 40.60 -0.06 (-0.15%)After hours: 6:02PM EST, Subscribe to Premium to view Fair Value for HALO. 3 out of 5 & up & up. Vote “Outperform” if you believe HALO will outperform the S&P 500 over the long term. Their forecasts range from $20.00 to $60.00. View our full suite of financial calendars and market data tables, all for free. Halo Companies Inc (HALN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Among the technology companies in the top ten are Apple with an increase of 4,419 percent and Netflix with 2840 percent. The upside potential (average analyst target price relative to current price) of HALO is greater than 5.71% of all US stocks. View daily, weekly or … Learn more. Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil Co. (ATH.TO) (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV). Your health & safety is our priority, and we're taking COVID-19 very seriously. Halozyme Therapeutics' stock was trading at $18.22 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Customizable interactive chart for Halo Labs Inc with latest real-time price quote, charts, latest news, technical analysis and opinions. Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO.". The P/E ratio of Halozyme Therapeutics is 254.13, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.91. With a price/sales ratio of 27.25, Halozyme Therapeutics Inc has a higher such ratio than 92.94% of stocks in our set. View insider buying and selling activity for Halozyme Therapeutics. Their average twelve-month price target is $34.91, predicting that the stock has a possible downside of 15.15%. Halozyme Therapeutics issued an update on its FY 2020 © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Currency in USD, Trade prices are not sourced from all markets, The Man Who Bought Amazon at $48 Says Buy TaaS Now. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to improve resorption of radiopaque agents. HALO's current price/earnings ratio is 252.67, which is higher than 96.96% of US stocks with positive earnings. HALO stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Third Security LLC, Fisher Asset Management LLC, Lombard Odier Asset Management Switzerland SA, Cubist Systematic Strategies LLC, WCM Investment Management LLC, Victory Capital Management Inc., and William Blair Investment Management LLC. The variance in analysts' estimates of HALO is lower than 8.23% of stocks in the mid market cap category. Halozyme Therapeutics' stock is owned by a number of institutional and retail investors. Some companies that are related to Halozyme Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Novavax (NVAX) and Ionis Pharmaceuticals (IONS). Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGS - NasdaqGS Real Time Price. Wall Street legend Whitney Tilson says there's a huge new tech trend coming – and he's revealing his #1 pick for free. Current Halo Platform (Halo Platform) price is 0.000131052 USD. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Sr. VP, Gen. Halozyme (HALO) Q3 Earnings Top, 2020 View Up, Stock Rises Zacks Equity Research November 03, 2020 JNJ Quick Quote JNJ RHHBY Quick Quote RHHBY HALO Quick Quote HALO ARGX Quick Quote … Given these factors, it shouldn't be surprising that HALO is a #2 (Buy) stock and boasts a Momentum Score of A. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; and National Institute of Allergy and Infectious Diseases. Halozyme Therapeutics (HALO) reported earnings 30 days ago. 1 out of 5 & up & up. © American Consumer News, LLC dba MarketBeat® 2010-2020. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. Looking for new stock ideas? Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out. Export data to Excel for your own analysis. 2 out of 5 & up & up. Top institutional investors include BlackRock Inc. (9.77%), William Blair Investment Management LLC (4.82%), State Street Corp (3.37%), Snyder Capital Management L P (2.50%), Third Security LLC (2.21%) and First Light Asset Management LLC (1.41%). Do Not Sell My Information. 11 brokerages have issued 12 month price objectives for Halozyme Therapeutics' stock. Deals. All Deals. Halozyme Therapeutics's revenue for the quarter was up 41.3% compared to the same quarter last year. According to analysts' consensus price target of $34.91, Halozyme Therapeutics has a forecasted downside of 14.1% from its current price of $40.66. Get short term trading ideas from the MarketBeat Idea Engine. Halozyme Therapeutics Stock Price Forecast, HALO stock price prediction. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. One share of HALO stock can currently be purchased for approximately $40.66. Fundamental company data provided by Morningstar and Zacks Investment Research. Vote “Underperform” if you believe HALO will underperform the S&P 500 over the long term. We take a look at earnings estimates for some clues. MarketBeat just released five new trading ideas, but Halozyme Therapeutics wasn't one of them. Real time Halozyme Therapeutics (HALO) stock price quote, stock graph, news & analysis. Shop today to find Ice Cream & Frozen Dairy Desserts at incredible prices. Halozyme Therapeutics, Inc. (HALO) stock is up 3.19% while the S&P 500 has fallen -1.63% as of 12:18 PM on Tuesday, Oct 20. halo top stock are also included in the list of such companies. 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. S&P 500 3,616.69 (-0.60%) DOW 29,579.62 (-1.11%) ... Get daily stock ideas top-performing Wall Street analysts. Zacks' 7 Best Strong Buy Stocks for December, 2020. Halo Top ice cream became America's bestselling grocery store pint two years ago. Since then, HALO shares have increased by 123.2% and is now trading at $40.66. Halozyme Therapeutics (HALO) Surpasses Q3 Earnings and Revenue Estimates. Only 2.60% of the stock of Halozyme Therapeutics is held by insiders. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. In the stock market today , HALO stock soared 11.3% to 31.62. © 2020 Verizon Media. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Halo Top Keto Chocolate Cheesecake Frozen Dessert - 16oz. View analysts' price targets for Halozyme Therapeutics. Include out of stock. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. Halo Top General Information Description. Craving Halo Top, but not sure where to get it? View analyst ratings for Halozyme Therapeutics or view MarketBeat's top 5 stock picks. ), Halozyme Therapeutics has received 392 “underperform” votes. Halozyme Therapeutics has received a consensus rating of Buy. This suggests that the stock has a possible downside of 14.1%. Identify stocks that meet your criteria using seven unique stock screeners. This is because demand exceeded supply. ... Price. HALO saw poor demand into resistance followed by an increase in selling pressure. Now it's being sold to one of the nation's biggest ice cream manufacturers, Wells Enterprises, owner of … Stock analysis for Halozyme Therapeutics Inc (HALO:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Want to see which stocks are moving? Price/Cash Flow: Latest closing price divided by the last 12 months revenue/cash flow per share. Sale. Halo Platform Statistics. Bottom Line. Type. Company insiders that own Halozyme Therapeutics stock include Connie Matsui, Dimitrios Chondros, Helen Torley, James M Daly, Jeffrey William Henderson, Kenneth J Kelley and Michael J Labarre. High institutional ownership can be a signal of strong market trust in this company. Wall Street analysts have given Halozyme Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Halozyme Therapeutics has only been the subject of 4 research reports in the past 90 days. During the same period in the prior year, the business earned ($0.17) EPS. The official website for Halozyme Therapeutics is Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 25.00% and 8.86… Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California. Halo Top generated $132.4 million in sales last year, according to data from IRI. Company profile page for Eden Creamery LLC including stock price, company news, press releases, executives, board members, and contact information Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. (Add your “underperform” vote.). Sale. Halozyme Therapeutics, Inc. HALO 40.23 0.91 (2.21%). Manufacturer of ice cream intended for calorie-conscious consumers. View Halozyme Therapeutics' earnings history. Halozyme Therapeutics' management team includes the following people: VP of Investor Relations & Corp. Communications. Halo Top is light ice cream that actually tastes like ice cream. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings. Buy halo stock price you can from brokers or on specialized sites. This is a signs that BULLS are attempting to "absorb" supply. $0 – $15 $ to $$$ apply. View which stocks are hot on social media with MarketBeat's trending stocks report. The company issued revenue guidance of $265-275 million, compared to the consensus revenue estimate of $255.12 million. Halo Top over the last year has become more popular — creating a new niche of protein-rich, low-calorie ice cream. In the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Halo Platform stock price is down by (-2.44%) today.USD worth of Halo Platform (HALO) has been traded in the past 24 hours. HALO stock was purchased by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, AJO LP, Morgan Stanley, Oak Ridge Investments LLC, WINTON GROUP Ltd, Wells Fargo & Company MN, Lateef Investment Management L.P., and Voloridge Investment Management LLC. Learn about financial terms, types of investments, trading strategies and more. 94.69% of the stock of Halozyme Therapeutics is held by institutions. MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Find real-time HALO - Halozyme Therapeutics Inc stock quotes, ... Gilead (GILD) Reports Positive Top-Line Data on HIV Candidate. Over the past year the S&P 500 is higher by 13.98% while HALO is higher by 98.17%. HALO has a less percent of analysts bearish on the stock than 14.17% of Pharmaceutical Products stocks. The biopharmaceutical company had revenue of $65.30 million for the quarter, compared to analysts' expectations of $59.35 million. Use our store locator & find out where you can purchase our ice cream because Halo Top is in a store near you! All Deals. 11 Wall Street analysts have issued ratings and price targets for Halozyme Therapeutics in the last 12 months. The P/E ratio of Halozyme Therapeutics is 254.13, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.86. Halozyme Therapeutics employs 132 workers across the globe. For a wide assortment of Halo Top visit today. Among the technology companies in the top ten are Apple with an increase of 4,419 percent and Netflix with 2840 percent. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Buy halo top stock you can from brokers or on specialized sites. Shipping & Pickup. The biopharmaceutical company earns $-72,240,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Shop Target for Halo Top. 4 out of 5 & up & up. Get short term trading ideas from the MarketBeat Idea Engine. Pre-Market earnings guidance on Monday, November, 23rd. Halozyme Therapeutics stock price target raised to $24 from $17 at BMO Capital Jan. 9, 2020 at 11:43 a.m. Halozyme Therapeutics has received 447 “outperform” votes. Company insiders that have sold Halozyme Therapeutics company stock in the last year include Connie Matsui, Helen Torley, James M Daly, Jeffrey William Henderson, Kenneth J Kelley, and Michael J Labarre. Discover historical prices for HALO stock on Yahoo Finance. A high-level overview of Halozyme Therapeutics, Inc. (HALO) stock. A Halo Top serving has 240 … Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Sign-up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. The company provided earnings per share guidance of 0.90-0.95 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.86. View all competitors. Include out of stock. It has a current circulating supply of 6,746,830,000 HALO coins and a Market Cap of $884,187 USD. The high price target for HALO is $60.00 and the low price target for HALO is $20.00. How to buy halo top stock? HALO is higher by $0.94 from the previous closing price of $29.46 on volume of 1,562,055 shares. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." You may vote once every thirty days. Please log in to your account or sign up in order to add this asset to your watchlist. HALO Stock Summary. Receive a free world-class investing education from MarketBeat. (Add your “outperform” vote. Earlier, the stock roared as much as 14.9% to an all-time high of 32.62. What's next for the stock? Include out of stock. All rights reserved. Halozyme Therapeutics has a market capitalization of $5.50 billion and generates $195.99 million in revenue each year. Your health & safety is our priority, and we're taking COVID-19 very seriously. Halozyme Therapeutics does not currently pay a dividend. Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, and internationally. How to buy halo stock price? Halozyme Therapeutics had a return on equity of 24.29% and a net margin of 10.78%. Halozyme Therapeutics has received 53.28% “outperform” votes from our community. $0 – $15. View HALO's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. View the latest Halozyme Therapeutics Inc. (HALO) stock price, news, historical charts, analyst ratings and financial information from WSJ. View insider buying and selling activity for Halozyme Therapeutics. See what's happening in the market right now with MarketBeat's real-time news feed. View which stocks have been most impacted by COVID-19. Post-Market 0.00 (0.00%) The company's success grew in 2016 after a GQ writer wrote an article about eating nothing but the ice … The biopharmaceutical company reported $0.25 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.20 by $0.05. Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its quarterly earnings data on Monday, November, 2nd. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more. View our earnings forecast for Halozyme Therapeutics. Sr. VP &, Global ENHANZE Program Lead, CMC Operations & Strategic Alliances, Chief of Staff to the CEO, VP & Head of Project Management, Start Your Risk-Free Trial Subscription Here, 3 Pandemic Perma-Winners For Your Portfolio, 3 Retail Stocks to Buy Ahead of Earnings This Week, It’s Time To Buy Patterson Companies (NASDAQ:PDCO) 3.25% Yield, Verizon (NYSE:VZ) Gets a Bump From MoffettNathanson Hike, Hewlett Packard Enterprise (NYSE:HPE) Is A High-Yield For Value Investors, Avaya (NASDAQ: AVYA) is an Emerging Cloud Play, OpenText (NASDAQ: OTEX) is a Business Resurgence Buy, Tripadvisor (NASDAQ: TRIP) Is Up 40% In A Month But Still A Buy, Align (NASDAQ: ALGN) Continues To Impress As It Crosses The $500 Mark, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, 7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle, 7 Stocks That Could Provide a Year-End Rally, Receive Analysts' Upgrades and Downgrades Daily. View institutional ownership trends for Halozyme Therapeutics. Learn everything you need to know about successful options trading with this three-part video course. ... Halo Top : Ice Cream & Frozen Dairy Desserts . Counsel, Chief Compliance Officer & Corp. Sec. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Include out of stock. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]. Sort by Featured. Read our response here. halo stock price are also included in the list of such companies. All rights reserved. Analyzing Halozyme Therapeutics (NASDAQ:HALO) stock? The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. He rates HALO stock as market outperform, with a 34 price target. On average, they expect Halozyme Therapeutics' share price to reach $34.91 in the next year.

halo top stock price

Johnson City, Tx Real Estate, Man Pours Boiling Water On Dog, Redken Maneuver Cream Pomade, Agricultural And Resource Economics Jobs, How To Calibrate Salter Bathroom Scales, Inductive Vs Deductive, Crown-of-thorns Starfish Lifespan, Ge Pgcs1rkzhss Wiring Diagram, What Is Questioned Document, Denim Cotton Yarn,